Table 1.
Trial Participant Characteristics at Baseline
| Intervention (N = 28) | Control (N = 28) | |
|---|---|---|
| Age, y | 56.2 (12.3) | 58.1 (9.9) |
| Female sex | 16 (57.1%) | 15 (53.6%) |
| Hispanic | 4 (14.3%) | 5 (17.9%) |
| Race | ||
| Asian | 5 (17.9%) | 5 (17.9%) |
| Black | 14 (50.0%) | 13 (46.4%) |
| White | 4 (14.3%) | 4 (14.3%) |
| Other | 5 (17.9%) | 6 (21.4%) |
| Smoking status | ||
| Current smoker | 2 (7.1%) | 0 (0.0%) |
| Never smoker | 15 (53.6%) | 13 (46.4%) |
| Smoked in past | 11 (39.3%) | 15 (53.6%) |
| Cause of chronic kidney disease | ||
| Diabetes | 10 (35.7%) | 7 (25.0%) |
| Glomerulonephritis | 2 (7.1%) | 6 (21.4%) |
| Hypertension or vascular disease | 6 (21.4%) | 5 (17.9%) |
| Other/unknown | 10 (35.7%) | 10 (35.7%) |
| Diabetes | 15 (53.6%) | 14 (50.0%) |
| Congestive heart failure | 4 (14.3%) | 5 (17.9%) |
| Cancer | 3 (10.7%) | 3 (10.7%) |
| Cardiovascular disease | 8 (28.6%) | 4 (14.3%) |
| Referred to dialysis education | 8 (28.6%) | 7 (25.0%) |
| Referred for dialysis access placement | 3 (10.7%) | 5 (17.9%) |
| Dialysis access placed | 2 (7.1%) | 4 (14.3%) |
| No. of home medications | 11.2 (4.9) | 10.4 (4.4) |
| eGFR, mL/min/1.73 m2 | 30.4 (9.8) | 31.1 (12.3) |
Note: Data presented as mean (standard deviation) and number (percent)
Abbreviation: eGFR, estimated glomerular filtration rate.